Verici Dx Plc (GB:VRCI) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Verici Dx Plc, a developer of advanced clinical diagnostics for organ transplant, has announced a delay in revenue recognition for its TutiviaTM test to FY25 due to a postponed Medicare coverage determination. Despite the delay, the company maintains a strong cash position and expects year-end balances to meet market expectations, with continued collaborations and anticipated revenue acceleration once insurance coverage is established in 2025.
For further insights into GB:VRCI stock, check out TipRanks’ Stock Analysis page.
